Analyst Price Targets — OPRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 10, 2025 10:54 am | — | UBS | $23.00 | $18.29 | TheFly | OptimizeRx price target raised to $23 from $20 at Citizens JMP |
| April 4, 2024 2:26 am | Constantine Davides | JMP Securities | $15.00 | $11.17 | StreetInsider | JMP Securities Starts OptimizeRX (OPRX) at Market Outperform, 'Comprehensive Biopharma Digital Marketing Platform' |
Latest News for OPRX
OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.3 per share a year ago.
WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2025.
WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2025.
OptimizeRx Corp. (NASDAQ: OPRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OPRX.
U.S. House Trading
No House trades found for OPRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.